The shares of Citigroup Inc. (NYSE:C) has been pegged with a rating of Outperform by Keefe Bruyette in its latest research note that was published on July 26th, 2019. The research company has also assigned a $86 price target. Keefe Bruyette wasn’t the only research firm that published a report of Citigroup Inc., with other equities research analysts also giving their opinion on the stock. Goldman advised investors in its research note published on May 30th, 2019, to Buy the C stock. The stock had earned Buy rating from Jefferies when it published its report on February 22nd, 2019. That day the Jefferies set price target on the stock to $73. The stock was given Outperform rating by Macquarie in its report released on January 7th, 2019. Barclays was of a view that C is Overweight in its latest report on January 2nd, 2019 while giving it a price target of $82. Standpoint Research thinks that C is worth Buy rating. This was contained in the firm’s report on December 26th, 2018.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 2 believe it has the potential for further growth, thus rating it as Hold while 12 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $83.40. The price of the stock the last time has raised by 32.53% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 33.51.
The shares of the company dipped by -2.85% during the trading session on Monday, reaching a low of $63.84 while ending the day at $64.17. During the trading session, a total of 12.44 million shares were traded which represents a 6.55% incline from the average session volume which is 13.31M shares. C had ended its last session trading at 66.05. Citigroup Inc. currently has a market cap of $146.48B, while its P/E ratio stands at 8.96, while its P/E earnings growth sits at 1.93, with a beta of 1.77. Citigroup Inc. debt-to-equity ratio currently stands at 1.36, while its quick ratio hovers at . C 52-week low price stands at $48.42 while its 52-week high price is $75.24.
The company in its last quarterly report recorded $1.83 earnings per share which is above the $1.80 predicted by most analysts. The Citigroup Inc. generated $18,758.00 million in revenue during the last quarter, which is slightly higher than the $18,494.80 million predicted by analysts. In the second quarter last year, the firm recorded $1.87 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -2.19%. Citigroup Inc. has the potential to record 7.16 EPS for the current fiscal year, according to equities analysts.
Investment analysts at SVB Leerink published a research note on July 22nd, 2019 where it informed investors and clients that Amneal Pharmaceuticals, Inc. (NYSE:AMRX) is now rated as Outperform. Their price target on the stock stands at $5. Goldman also rated AMRX as Upgrade on May 30th, 2019, with its price target of suggesting that AMRX could surge by 45.7% from its current share price. Even though the stock has been trading at $2.91/share, analysts expect it to surge higher by -2.58% to reach $5.23/share. It started the day trading at $2.94 and traded between $2.79 and $2.84 throughout the trading session.
A look at its technical shows that AMRX’s 50-day SMA is 5.37 while its 200-day SMA stands at 11.89. At the moment, only of Amneal Pharmaceuticals, Inc. shares were sold short. The company’s average trading volume currently stands at 1.95M shares, which means that the short-interest ratio is just 3.75 days. Over the past seven days, the company moved, with its shift of -6.13%. Looking further, the stock has dropped -68.18% over the past 90 days while it lost -78.52% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. T Rowe Price Associates Inc bought more AMRX shares, increasing its portfolio by +1.22% during the last quarter. This move now sees T Rowe Price Associates Inc purchasing 239,722 shares in the last quarter, thus it now holds 19,861,418 shares of AMRX, with a total valuation of $142,406,367. Wellington Management Co LLP meanwhile sold more AMRX shares in the recently filed quarter, changing its stake to $114,055,198 worth of shares. The Vanguard Group Inc followed the path by increasing its AMRX portfolio by +4.86% in the quarter. This means that The Vanguard Group Inc bought 433,474 shares in the last quarter and now controls 9,357,940 shares of the AMRX stock, with the valuation hitting $67,096,430.
Similarly, BlackRock Fund Advisors decreased its Amneal Pharmaceuticals, Inc. shares by -3.39% during the recently filed quarter. After selling -185,638 shares in the last quarter, the firm now controls 5,290,289 shares of Amneal Pharmaceuticals, Inc. which are valued at $37,931,372. In the same vein, SSgA Funds Management Inc decreased its Amneal Pharmaceuticals, Inc. shares by during the most recent reported quarter. The firm sold -98,901 shares during the quarter which decreased its stakes to 1,940,492 shares and is now valued at $13,913,328. Following these latest developments, around 0.60% of Amneal Pharmaceuticals, Inc. stocks are owned by institutional investors and hedge funds.